PREVALENCE OF POSITIVITY OF CBNAAT IN PULMONARY TUBERCULOSIS

Background: TB Is the ninth leading cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS. In 2016, there were an estimated 1.3 million TB deaths among HIV negative people (down from 1.7 million in 2000) and an additional 374 000 deaths among HIV-positive people. Methods: This is a retrospective study conducted in the department of Pulmonary medicine. Early morning sputum sample was collected from the patients in a clean sterile container. Results: Among the total 500 samples, 110 were detected tuberculosis positive by CBNAAT method and 390 were negative. And among 110 positive cases, 107 were Rifampicin sensitive and 3 were Rifampicin resistant Conclusion: CBNAAT detects pulmonary TB with greater efficacy than sputum microscopy also helping in early diagnosis in less than 2 hours. It also detects rifampicin resistance with high specificity and can be used for screening for MDR-TB so that early therapy can be started thus decreasing the incidence of MDR-TB. WHO recommends CBNAAT for early diagnosis of pulmonary tuberculosis and detection of rifampicin resistance and retreatment cases, who are at risk of MDR-TB. Keywords: CBNAAT, MDR, Pulmonary tuberculosis